

**PRELIMINARY AMENDMENT**

**U.S. Appln. No. 09/674,377**

- CK*
- (b) a polypeptide having an amino acid sequence derived from the amino acid sequence defined in (a) by the deletion, substitution or addition of one or more amino acids.
- 

**REMARKS**

The specification has been amended to correct obvious typographical errors therein. New Claims 19-37 has been added. Hence, the amendments to the specification and the addition of new Claims 19-37 do not constitute new matter, and entry is respectfully requested.

The Examiner is invited to contact the undersigned at the below-listed number on any questions which might arise.

Respectfully submitted,

  
\_\_\_\_\_  
Gordon Kit

Registration No. 30,764

**SUGHRUE MION, PLLC**

2100 Pennsylvania Avenue, N.W.

Washington, D.C. 20037-3213

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

Date: May 30, 2002



## A P P E N D I X

### Marked-Up Version of Changes

#### IN THE SPECIFICATION:

The specification is changed as follows:

Page 6, lines 10-14, are being amended as follows:

"Fig. 13 indicates that HGF/NK4 has the action to inhibit the growth (A) and [metastatis] metastasis (B) of Jyg mammary tumor cells; A shows the time course of the volume of a transplanted tumor mass and B shows the number of metastatic foci."

Pages 21, line 24 to Page 23, line 2, are amended as follows:

"Regarding the manufacture of tablets, the carrier that can be used includes various excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silica, etc.; binders such as simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone, etc.; disintegrators such as dried starch, sodium alginate, agar powder, laminaran powder, sodium hydrogencarbonate, calcium carbonate, polyethoxylated sorbitan fatty acid esters, sodium lauryl sulfate, stearyl monoglyceride, starch, lactose, etc.; disintegration inhibitors such as sucrose, stearic acid, cacao butter, hydrogenated oil, etc.; absorption promoters such as quaternary ammonium bases, sodium lauryl sulfate, etc.; humectants such as glycerin, starch, etc.; adsorbents such as starch, lactose, kaolin, bentonite, colloidal silica, etc.; and lubricants such as purified [talk] talc, salts of stearic acid, boric acid powder, polyethylene glycol and so on. Furthermore,

where necessary, tablets may be manufactured in the form of coated tablets, i.e., tablets carrying a conventional surface coating, such as sugar-coated tablets; gelatin-coated tablets; film-coated tablets, etc., or in the form of double-layered or multi-layered tablets."

Page 26, line 24 to page 27, line 16, are amended as follows:

"The neovascularization inhibitor of the present invention can be applied to the prophylaxis and therapy of a broad spectrum of diseases arising from vascular hyperplasia. Although such diseases are not particularly restricted, there can be mentioned rheumatoid arthritis, psoriasis, Osler-Webber syndrome, myocardial angiopoiesis, telangiectasia, hemophilic joint, angiogenic diseases of the eye (e.g. diabetic retinopathy, retinopathy of prematurity, senile macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, etc.), angiofibroma, benign tumors (e.g. hemangioma, acoustic neuroma, neurofibroma, trachoma, granuloma pyogenicum, etc.), hematopoietic malignancies such as leukemia, solid cancers, cancer [metastases] metastasis and wound granulation, among others."

**IN THE CLAIMS:**

New Claims 19-37 are being added.